Clinical Trial Update: Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure [Phase 3]

View source ↗

Summary

Phase 3 trial of TD-9855 for symptomatic neurogenic orthostatic hypotension was terminated; results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple System Atrophy
• Parkinson Disease
• Pure Autonomic Failure
• Symptomatic Neurogenic Orthostatic Hypotension

Drugs mentioned

• TD-9855

Snippet

Sponsor: Theravance Biopharma | Conditions: Symptomatic Neurogenic Orthostatic Hypotension, MSA | Phase 3 | Status: TERMINATED | Results posted: 2023-01-20